Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    21176949 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Suspended BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)
Condition: Follicular Lymphoma
Intervention: Drug: BeEAM
2 Active, not recruiting Primary Rituximab and Maintenance
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: rituximab

Indicates status has not been verified in more than two years